Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on November 2, 2016, to report its financial results for the quarter ended September 30, 2016. This filing primarily serves to furnish the press release detailing these results, which is incorporated by reference. While the 8-K itself does not contain the detailed financial figures, it signifies the public release of the company's performance data for the period. Investors should refer to the furnished press release (Exhibit 99.1) for specific information regarding revenue, expenses, net income/loss, and any forward-looking statements or strategic updates provided by Alnylam for that quarter.
Key Highlights
- 1Alnylam Pharmaceuticals announced its financial results for the third quarter of 2016 via press release on November 2, 2016.
- 2The 8-K filing serves to officially report the availability of these financial results.
- 3The press release detailing the financial results for the quarter ended September 30, 2016, is furnished as Exhibit 99.1.
- 4Information contained in the press release is not deemed 'filed' for certain SEC liability purposes, but is provided for investor awareness.
- 5Investors need to consult Exhibit 99.1 for the actual financial performance data and any related commentary from Alnylam.
- 6The filing is a standard disclosure of quarterly earnings by a publicly traded company.
Frequently Asked Questions
The main purpose of this 8-K filing is to publicly announce and furnish Alnylam Pharmaceuticals' financial results for the third quarter of 2016, which ended on September 30, 2016. It makes the accompanying press release available to investors and the public.
The specific financial details for the quarter ended September 30, 2016, are contained within the press release dated November 2, 2016, which is provided as Exhibit 99.1 to this 8-K filing. Investors should refer to this exhibit for information on revenue, net loss, cash position, and other financial metrics.
This 8-K filing, as it pertains to Item 2.02 (Results of Operations and Financial Condition), primarily focuses on reporting the financial results. While the accompanying press release may contain some operational or strategic commentary, the 8-K itself does not introduce new information beyond the earnings announcement and related financial data. For comprehensive strategic updates, investors should carefully review the content of Exhibit 99.1.